ESC Premium Access

Clinical Trial Update 2

Event: ESC CONGRESS 2017
Topic: Miscellaneous
Session type: Clinical Trial Update
Date: 29 August 2017
Time: 16:30 - 18:00

Congress Session

6 presentations in this session

Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen of Naproxen

Speaker: Professor S. Nissen (Cleveland, US)

Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV trial

Speaker: Professor S. Nicholls (Melbourne, AU)

Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects WithElevated Risk

Speaker: Professor T. Pedersen (Oslo, NO)

Empagliflozin reduces mortality in patients with type 2 diabetes after coronary artery bypass graft surgery: A sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)

Blood Pressure Levels for Initiation of Antihypertensive Drug Therapy and Targets of Blood Pressure Lowering in Intermediate Risk People without Cardiovascular Disease: Insights from the HOPE-3 Trial

Speaker: Professor E. Lonn (Hamilton, CA)

One year clinical outcome of Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.

Speaker: Doctor V. Roolvink (Zwolle, NL)

6 speakers from this session

Professor Steven E Nissen

Cleveland Clinic Foundation, Cleveland (United States of America)
11 presentations
0 follower

Professor Stephen Nicholls

Monash Heart, Melbourne (Australia)
36 presentations
1 follower

Professor Terje Rolf Pedersen

Ulleval University Hospital, Oslo (Norway)
4 presentations
0 follower

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)
20 presentations
0 follower

Professor Eva Lonn

Population Health Research Institute, Hamilton (Canada)
1 presentation
0 follower

Doctor Vincent Roolvink

Isala Hospital, Zwolle (Netherlands (The))
1 presentation
0 follower

This platform is supported by

logo Novo Nordisk